A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis

This will be a randomized, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resolution magnetic resonance imaging in women with endometrioma, deep infiltrating endometriosis, and/or adenomyosis.

开始日期2019-08-19

申办/合作机构

Ferring Pharmaceuticals A/S

EUCTR2018-000915-26-DE

/ Not yet recruiting临床2期

A randomised, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resolution magnetic resonance imaging in women with endometrioma, deep infiltrating endometriosis, and/or adenomyosis

开始日期2019-05-10

申办/合作机构

Ferring Pharmaceuticals A/S

NCT03692403

/ Completed临床2期

A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Assessing the Efficacy, Safety and Dose-response of Quinagolide Extended-release Vaginal Rings Administered Sequentially for 4 Menstrual Cycles in Women With Moderate to Severe Endometriosis-related Pain

To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain

开始日期2018-12-26

申办/合作机构

Ferring Pharmaceuticals A/S

100 项与盐酸喹高利特相关的临床结果

登录后查看更多信息

100 项与盐酸喹高利特相关的转化医学

登录后查看更多信息

100 项与盐酸喹高利特相关的专利（医药）

登录后查看更多信息

280

项与盐酸喹高利特相关的文献（医药）

2025-06-01·European Journal of Obstetrics & Gynecology and Reproductive Biology

Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial

Article

作者: Alberich-Bayarri, Angel ; Pellicer, Antonio ; Bagger, Yu Z ; Pinton, Philippe ; Barletta, Kathryn E ; Taylor, Hugh S ; Liu, Yan ; Gamborg, Michael ; Heiser, Patrick W

BACKGROUNDThis study evaluated the effectiveness of quinagolide vaginal ring on reducing total lesion size in endometrioma, deep infiltrating endometriosis (DIE), and adenomyosis, as assessed using high-resolution MRI and imaging biomarkers.METHODSQLARITY was a randomized, double-blind, placebo-controlled, phase 2 trial. Patients aged 18-45 years with endometrioma, DIE, and/or adenomyosis were randomized to quinagolide or placebo and monitored for four menstrual cycles. The primary endpoint was reduction in total lesion size. Secondary endpoints were pain reduction, changes in prolactin, changes in menstrual cycle, bleeding patterns, and safety. Exploratory analyses identified MRI-derived perfusion and diffusion-weighted imaging biomarkers.RESULTSOf the 67 included subjects, 35 received quinagolide vaginal ring and 32 received placebo. No significant differences were noted between groups for the primary endpoint of reduction in lesion size. No significant differences were observed between groups in terms of patient-reported outcomes, serum prolactin levels, menstrual bleeding patterns, or adverse events. Exploratory analyses suggested lesions in the placebo group showed a greater increase in vascular permeability and worsening lesion structure.CONCLUSIONSOur primary analysis showed no significant difference between treatment groups in terms of change in total lesion size. Many patients in this study presented with advanced disease, which may be less responsive to quinagolide than highly vascularized superficial lesions, as quinagolide inhibits the VEGF signaling pathway.TRIAL REGISTRATIONClinicalTrials.gov NCT03749109.

2025-01-01·Journal of Dairy Science

Effect of prolactin concentration during the dry period on the subsequent milk production of dairy cows

Article

作者: Lanctôt, S ; Deacon, A-M ; Deacon, A.-M. ; Lanctôt, S. ; Thibault, C ; Thibault, C. ; Blouin, R. ; Lacasse, P. ; Blouin, R ; Lacasse, P

Shortening the dry period has a negative effect on milk production of the following lactation. One possible explanation is that a period of low prolactin (PRL) concentration is necessary to restore mammary gland milk production capacity. Therefore, the objective of this study was to determine the effect of lowering blood PRL level on subsequent lactation milk production. In this experiment, quinagolide was used to inhibit PRL secretion during the dry period. Thirty Holstein cows were randomly assigned one of 3 dry period managements: a conventional (60 d) dry period (CD) and 2 short (35 d) dry period treatments (SDP). Short dry period cows received either water (SDwater) or quinagolide (2 mg, SDquin) injections twice daily from dry-off until 14 d before calving. Cows were followed during the first 20 wk of the subsequent lactation. When CD cows were dry but SDP cows were lactating, concentration of PRL was lower in the CD cows than in the SDP cows. During the injection period, PRL of SDquin cows was lower than that of the other treatments and was greater in the blood of SDwater than in that of CD cows. After the injection period until calving, no difference in PRL concentration was observed between treatments. After calving, PRL concentration of the SDquin cows was greater than those of CD and SDwater cows. During the first 20 wk of lactation, ECM was lower in SDwater cows than in CD and SDquin cows. The ECM of the latter groups were not different. During the same period, mammary expression of genes related to milk synthesis, pro-apoptotic genes, as well as the expression of the short and long isoforms of the PRLR genes were not affected; however, the expression of SOCS3 gene tended to be lower for the SDquin than the SDwater cows. Lowering the PRL level during short dry period restored milk production to the level normally observed after a conventional dry period, which suggests that higher PRL levels during short dry period are the cause of the lower milk production after a short dry period. Ultimately, strategies to lower blood PRL level may help the adoption of short dry period.

2024-02-16·The Journal of Organic Chemistry

Streamlined Stereoselective Entry to (−)-Quinagolide and to 3-Substituted Octahydrobenzo[g]-Quinolines

Article

作者: Pineschi, Mauro ; Ryberg, Per ; Comparini, Lucrezia Margherita ; Favero, Lucilla ; Di Pietro, Sebastiano ; Sardelli, Francesca

A very short stereoselective synthesis of enantiomerically pure (3S, 4aS, 10aR)-quinagolide has been developed. The key steps involved are a copper-catalyzed regioselective arylation of (S)-epichlorohydrin with 1,6-dimethoxynaphthalene and a diastereoselective trans-reduction of a cyclic enamine intermediate. The possibility to use both enantiomers of epichlorohydrin and the diastereodivergency found in the reduction process paves the way for a general preparation also in the nonracemic form of chiral trans-fused 3-substituted octahydrobenzo[g]quinolines that are privileged structures in medicinal chemistry.

项与盐酸喹高利特相关的新闻（医药）

2025-01-29

·PRNewswire

Endometriosis Clinical Trial Pipeline Gains Momentum as 15+ Key Companies at the Forefront | DelveInsight

Approximately 10% of women of reproductive age worldwide are affected by endometriosis, equating to about 190 million individuals. This substantial patient population necessitates effective treatments, propelling market demand this increasing disease prevalence is driving the market for endometriosis. LAS VEGAS, Jan. 29, 2025 /PRNewswire/ -- DelveInsight's ' Endometriosis Pipeline Insight 202 5 ' report provides comprehensive global coverage of pipeline endometriosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the endometriosis pipeline domain. Key Takeaways from the Endometriosis Pipeline Report DelveInsight's endometriosis pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for endometriosis treatment. Key endometriosis companies such as Kissei Pharmaceutical, Mithra Pharmaceuticals, Gesynta Pharma, Jiangsu Hengrui Medicine Co., Ferring Pharmaceuticals, Hope Medicine (Nanjing) Co., Ltd, VaRi Bioscience, SWK Holdings, Ananda Developments, TiumBio, Ironwood Pharmaceuticals, Chugai Pharmaceutical, Viramal, Organon, Mitsubishi Tanabe Pharma, Antev, Foraviset, ValiRx, EpicentRx, Temple Therapeutics, Celmatix, BCI Pharma, Gynica, PrecisionLife, Flightpath Biosciences, and others are evaluating new endometriosis drugs to improve the treatment landscape. Promising endometriosis pipeline therapies such as Linzagolix, Estelle, Vipoglanstat, SHR7280, Quinagolide, HMI-115, VR103, Ovarest, MRX1, TU2670, IW-3300, AMY-109, VML 0501, OG-6219, Teverelix trifluoroacetate, Raviset, VAL301, Nibrozetone, TTX334e, IntraVagS302, IntraVagS301, FP-300, and others are under different phases of endometriosis clinical trials. In October 2024, Lisata Therapeutics, Inc. announced that it has entered into a sponsored research agreement with the University of Cincinnati to investigate Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor) in a preclinical animal model for the treatment of endometriosis. In October 2024, Hope Medicine Inc. announced positive results from an interim analysis of a global Phase II study, " A Randomized, Multicenter, Double-Blind, Placebo -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women with Moderate to Severe Endometriosis Associated Pain Over a 12-Week Treatment Period". HMI-115 is a monoclonal antibody that blocks the prolactin receptor. It is a first-in-class treatment for endometriosis. Notably, HMI-115 has been granted Breakthrough Therapy Designation by the National Medical Products Administration ("NMPA") in China. In May 2024, Neurocrine Biosciences, Inc. announced the initiation of its Phase I first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants. NBI-1117567 is an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist for the potential treatment of neurological and neuropsychiatric conditions. In May 2024, TiumBio Co., Ltd. focused on discovering and developing innovative therapeutics for patients with rare and incurable diseases, announced positive topline results from its Phase 2a clinical trial of Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in patients with moderate to severe endometriosis-associated pain. Request a sample and discover the recent advances in endometriosis treatment drugs @ Endometriosis Pipeline Report The endometriosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage endometriosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the endometriosis clinical trial landscape. Endometriosis Overview Endometriosis is a condition where tissue similar to the endometrium, which lines the uterus, grows outside of it. This often occurs in the lower abdomen or pelvic region but can occasionally be found elsewhere in the body. It commonly causes pelvic pain and may lead to infertility. The condition can begin with a person's first menstrual cycle and persist until menopause. The exact cause of endometriosis remains unknown, and there is currently no way to prevent it. While there is no cure, symptoms can be managed through medications or, in some cases, surgery. Not all individuals with endometriosis experience symptoms, but common ones include pelvic pain, painful periods, discomfort during sexual intercourse, and challenges with conception. Approximately 10% of women of reproductive age are affected, though the true prevalence is difficult to determine as diagnosis often requires laparoscopic surgery to confirm the presence of lesions. Endometriosis is a complex and widespread condition affecting women worldwide, regardless of ethnicity or social status. It is believed to result from multiple factors, including retrograde menstruation and cellular metaplasia, where cells outside the uterus transform into endometrial-like tissue. The condition is also heavily influenced by estrogen, which promotes inflammation, growth, and pain associated with the disease. Diagnosing endometriosis typically involves assessing a patient's menstrual and pelvic pain history. Although various diagnostic tools have been proposed, none are fully validated to identify individuals with certainty. Symptoms can mimic other conditions, leading to diagnostic delays. Imaging techniques like ultrasonography or MRI may be used to detect ovarian endometriomas, adhesions, or deep nodular lesions. Histologic confirmation, often following laparoscopic visualization, helps confirm the diagnosis but should not delay the initiation of empirical medical treatment. Treatment options range from conservative approaches, such as non-steroidal anti-inflammatory drugs (e.g., ibuprofen) to manage pain, to hormone-based medications that help control symptoms. Surgical intervention can both diagnose and treat endometriosis, with procedures to remove or destroy lesions and scar tissue, potentially alleviating pain and restoring normal pelvic anatomy. Find out more about endometriosis treatment drugs @ Drugs for Endometriosis Treatment A snapshot of the Endometriosis Pipeline Drugs mentioned in the report: Learn more about the emerging endometriosis pipeline therapies @ Endometriosis Clinical Trials Endometriosis Therapeutics Assessment The endometriosis pipeline report proffers an integral view of the endometriosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Endometriosis Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: LHRH receptor antagonists, Estrogen receptor agonists, Hormone replacements, Mineralocorticoid receptor antagonists, Progesterone receptor agonists, Testosterone congener inhibitors, Prostaglandin-E synthase inhibitors, Gonadotropin-releasing hormone inhibitors, Dopamine D2 receptor agonists, Prolactin receptor antagonists, Key Endometriosis Companies: Kissei Pharmaceutical, Mithra Pharmaceuticals, Gesynta Pharma, Jiangsu Hengrui Medicine Co., Ferring Pharmaceuticals, Hope Medicine (Nanjing) Co., Ltd, VaRi Bioscience, SWK Holdings, Ananda Developments, TiumBio, Ironwood Pharmaceuticals, Chugai Pharmaceutical, Viramal, Organon, Mitsubishi Tanabe Pharma, Antev, Foraviset, ValiRx, EpicentRx, Temple Therapeutics, Celmatix, BCI Pharma, Gynica, PrecisionLife, Flightpath Biosciences, and others. Key Endometriosis Pipeline Therapies: Linzagolix, Estelle, Vipoglanstat, SHR7280, Quinagolide, HMI-115, VR103, Ovarest, MRX1, TU2670, IW-3300, AMY-109, VML 0501, OG-6219, Teverelix trifluoroacetate, Raviset, VAL301, Nibrozetone, TTX334e, IntraVagS302, IntraVagS301, FP-300 and others. Dive deep into rich insights for new drugs for endometriosis treatment, visit @ Endometriosis Drugs Table of Contents For further information on the endometriosis pipeline therapeutics, reach out @ Endometriosis Treatment Drugs Related Reports Endometriosis Market Endometriosis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key endometriosis companies including AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, among others. Endometriosis Epidemiology Forecast Endometriosis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted endometriosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Endometriosis Pain Market Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others. Endometriosis Pain Pipeline Endometriosis Pain Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床结果突破性疗法临床1期

2024-01-02

·SYNAPSE

D2 receptor agonists: What They Are and How to Stay Updated on the Latest Research

The D2 receptor is a type of dopamine receptor found in the human body. It plays a crucial role in various physiological and neurological processes. As a G-protein coupled receptor, the D2 receptor is involved in the regulation of dopamine neurotransmission, which affects mood, motivation, and reward. Dysfunction of the D2 receptor has been implicated in several psychiatric disorders, including schizophrenia and addiction. Additionally, the D2 receptor is a target for antipsychotic medications, which work by blocking its activity to alleviate symptoms of psychosis. Understanding the role of the D2 receptor is essential for developing therapeutic interventions for psychiatric and neurological conditions. D2 receptor agonists are a class of drugs that activate the D2 subtype of dopamine receptors. They are primarily used in the treatment of Parkinson’s disease, hyperprolactinemia, and restless legs syndrome. The first D2 receptor agonist, bromocriptine, was approved by the FDA in 2009 for the treatment of type 2 diabetes. The analysis of the target D2 receptor reveals a competitive landscape with multiple companies making progress in the development of drugs. Johnson & Johnson, Mitsubishi Chemical Group Corp., Novartis AG, Sanofi, and Viatris Inc. have shown significant growth and have drugs approved for the target. Schizophrenia, bipolar disorder, and bipolar I disorder are the most common indications for approved drugs. Small molecule drugs are progressing rapidly, with intense competition from biosimilars. The United States, Japan, and China are the leading countries in the development of drugs targeting the D2 receptor, with China showing notable progress. Overall, the target D2 receptor presents opportunities for further research and development in the pharmaceutical industry. How do they work?D2 receptor agonists are a type of medication that specifically target and activate the D2 receptors in the brain. D2 receptors are a subtype of dopamine receptors, which are involved in the regulation of various neurological processes, including movement, mood, and reward. By acting as agonists, these medications enhance the activity of D2 receptors, leading to increased dopamine signaling in the brain. From a biomedical perspective, D2 receptor agonists are commonly used in the treatment of conditions related to dopamine dysregulation, such as Parkinson's disease and certain psychiatric disorders. In Parkinson's disease, the loss of dopamine-producing cells in the brain leads to motor symptoms. D2 receptor agonists can help alleviate these symptoms by stimulating the remaining D2 receptors and compensating for the reduced dopamine levels. In psychiatric disorders like schizophrenia, abnormal dopamine signaling is believed to play a role. D2 receptor agonists can modulate dopamine activity and help manage symptoms such as hallucinations and delusions. These medications may be used in combination with other antipsychotic drugs to provide comprehensive treatment. Overall, D2 receptor agonists have therapeutic effects by selectively targeting and activating D2 receptors, thereby influencing dopamine signaling in the brain. List of D2 receptor AgonistsThe currently marketed D2 receptor agonists include: Aripiprazole LauroxilCariprazine hydrochlorideBrexpiprazoleRotigotineAripiprazoleZiprasidone HydrochlorideQuinagolide HydrochloridePramipexole DihydrochlorideRopinirole HydrochlorideTalipexole HydrochlorideFor more information, please click on the image below. What are D2 receptor agonists used for?D2 receptor agonists are commonly used in the treatment of conditions related to dopamine dysregulation, such as Parkinson's disease and certain psychiatric disorders. For more information, please click on the image below to log in and search. How to obtain the latest development progress of D2 receptor agonists?In the Synapse database, you can keep abreast of the latest research and development advances of D2 receptor agonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

2023-11-08

·SYNAPSE

Analysis on the Research Progress of D2 Receptor Agonist

The D2 receptor is a type of dopamine receptor found in the human body. It plays a crucial role in various physiological and neurological processes. The D2 receptor is a postsynaptic receptor that is highly expressed in the striatum. Activation of D2R can lead to signal pathways related to cell differentiation, growth, metabolism, and apoptosis. D2R also plays an important role in dopaminergic neurotransmission and motor control. As a G-protein coupled receptor, the D2 receptor is involved in the regulation of dopamine neurotransmission, which affects mood, motivation, and reward. Dysfunction of the D2 receptor has been implicated in several psychiatric disorders, including schizophrenia and addiction. Additionally, the D2 receptor is a target for antipsychotic medications, which work by blocking its activity to alleviate symptoms associated with psychosis. Understanding the role of the D2 receptor is essential for developing therapeutic interventions for psychiatric and neurological conditions. D2 receptor Competitive LandscapeAccording to Patsnap Synapse, as of 14 Oct 2023, there are a total of 277 D2 receptor drugs worldwide, from 320 organizations, covering 179 indications, and conducting 3922 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. The analysis of the target D2 receptor reveals a competitive landscape with multiple companies making progress in the development of drugs. Johnson & Johnson, Mitsubishi Chemical Group Corp., and Novartis AG have shown the highest stage of development, with multiple approved drugs. The most common indications for approved drugs are schizophrenia, bipolar disorder, bipolar I disorder, and Parkinson's disease. Small molecule drugs dominate the development pipeline, indicating intense competition around innovative drugs. Synthetic peptides and fusion proteins also show some progress. The United States, Japan, China, and the European Union are the leading countries/locations in the development of drugs targeting the D2 receptor, with China showing significant progress. Overall, the target D2 receptor presents opportunities for further research and development, particularly in indications such as schizophrenia, bipolar disorder, and Parkinson's disease. The competitive landscape is dynamic, with companies and countries actively contributing to the advancement of drugs targeting the D2 receptor. The world's only transdermal patch for Parkinson's: RotigotineRotigotine is a small molecule drug that targets the D2 receptor. It is primarily used in the treatment of nervous system diseases and endocrinology and metabolic diseases. The drug has been approved for the treatment of Parkinson's disease and restless legs syndrome. Rotigotine was first approved in the European Union in February 2006. It is developed by UCB SA, a pharmaceutical company specializing in the research and development of innovative medicines. The drug has also received approval in China. The approval of Rotigotine in both the European Union and China indicates its efficacy and safety in treating Parkinson's disease and restless legs syndrome. The drug's mechanism of action involves targeting the D2 receptor, which is involved in the regulation of movement and mood. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. The therapeutic areas of nervous system diseases and endocrinology and metabolic diseases encompass a wide range of conditions, including neurological disorders and hormonal imbalances. Rotigotine's approval in these therapeutic areas suggests its potential to address various medical needs within these fields. The fact that Rotigotine has reached the highest phase of development, which is approved, indicates that it has successfully undergone rigorous clinical trials and met the necessary regulatory requirements. The drug's approval status also suggests that it has demonstrated significant efficacy and safety in treating Parkinson's disease and restless legs syndrome. The priority review designation further highlights the importance and potential impact of Rotigotine in the pharmaceutical industry. This designation is typically granted to drugs that address unmet medical needs or provide significant advancements in treatment options. In summary, Rotigotine is a small molecule drug that targets the D2 receptor and is approved for the treatment of Parkinson's disease and restless legs syndrome. Developed by UCB SA, the drug has received approval in both the European Union and China. Its approval status and priority review designation indicate its efficacy and potential impact in the field of biomedicine. Quinagolide HydrochlorideQuinagolide Hydrochloride is a small molecule drug that primarily targets the D2 receptor. It has been approved for use in the treatment of various diseases related to the nervous system, urogenital system, neoplasms, endocrinology, metabolic diseases, and other conditions. The drug has shown efficacy in treating specific indications such as prolactinoma, hyperprolactinemia, endometriosis, adenomyosis, and pain. Quinagolide Hydrochloride received its first global approval in September 1997 in South Africa. Since then, it has been used in clinical settings to address the aforementioned conditions. As a small molecule drug, it is designed to interact with the D2 receptor, which plays a crucial role in regulating various physiological processes. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Prolactinoma, a condition characterized by the overproduction of prolactin hormone, can lead to infertility, menstrual irregularities, and other complications. Quinagolide Hydrochloride has been found to effectively reduce prolactin levels, thereby alleviating the symptoms associated with this condition. Hyperprolactinemia, a condition characterized by abnormally high levels of prolactin hormone, can also be effectively managed with Quinagolide Hydrochloride. By targeting the D2 receptor, the drug helps regulate prolactin secretion, restoring hormonal balance and improving patient outcomes. Endometriosis and adenomyosis are conditions that affect the female reproductive system, causing pain, inflammation, and fertility issues. Quinagolide Hydrochloride has shown promise in managing these conditions by reducing pain and inflammation, improving quality of life, and potentially preserving fertility. Additionally, Quinagolide Hydrochloride has demonstrated potential in the treatment of various neoplasms, endocrinology, metabolic diseases, and other conditions. However, further research and clinical trials are needed to fully understand its efficacy and safety profile in these areas. Overall, Quinagolide Hydrochloride is an approved small molecule drug that targets the D2 receptor. It has shown effectiveness in treating various conditions related to the nervous system, urogenital system, neoplasms, endocrinology, metabolic diseases, and other diseases. Its approval in South Africa in 1997 marked an important milestone in the pharmaceutical industry, providing healthcare professionals with a valuable tool in managing specific indications such as prolactinoma, hyperprolactinemia, endometriosis, adenomyosis, and pain.

100 项与盐酸喹高利特相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	盐酸喹高利特	G02CB04	DB09097

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高催乳素血症	南非	Novartis AG	1997-09-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
子宫腺肌病	临床前	波兰	Ferring Pharmaceuticals A/S	2019-08-19
子宫腺肌病	临床前	丹麦	Ferring Pharmaceuticals A/S	2019-08-19
子宫腺肌病	临床前	意大利	Ferring Pharmaceuticals A/S	2019-08-19
子宫内膜异位症	临床前	波兰	Ferring BV	2019-06-21
子宫内膜异位症	临床前	意大利	Ferring BV	2019-06-21
子宫内膜异位症	临床前	德国	Ferring BV	2019-06-21
子宫内膜异位症	临床前	丹麦	Ferring BV	2019-06-21
疼痛	临床前	美国	Ferring Pharmaceuticals A/S	2018-12-26
卵巢过度刺激综合征	临床前	西班牙	Ferring Pharmaceuticals A/S	2006-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03749109 (QLARITY, CTgov)	临床2期	子宫内膜异位症 \| 子宫腺肌病	67	Quinagolide 1080 µg (Quinagolide 1080 µg)	鏇淵鹽繭繭艱遞繭憲窪(鏇蓋願艱築夢網構鏇膚) = 顧餘艱淵蓋範範積獵壓積鹽夢鑰選壓廠窪積製 (廠淵壓築積淵繭築壓淵, 廠獵夢糧衊範願願積繭 ~ 鹽觸簾淵窪範衊鹽膚獵) 更多	-	2022-09-07
				Placebo (Placebo)	鏇淵鹽繭繭艱遞繭憲窪(鏇蓋願艱築夢網構鏇膚) = 餘蓋餘窪餘獵觸蓋艱簾積鹽夢鑰選壓廠窪積製 (廠淵壓築積淵繭築壓淵, 網壓構範繭糧鑰願獵範 ~ 糧廠選願窪夢構製顧醖) 更多